IGFL2-AS1

Across TCGA pan-cancer cohorts, IGFL2-AS1 RNA differs between tumor and matched normal tissue in 9 of 18 cancer types tested, making tumor–normal expression one of IGFL2-AS1’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where IGFL2-AS1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types IGFL2-AS1 is over-expressed in tumor.

HNSC, COAD, and BLCA are the cancer types where IGFL2-AS1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in IGFL2-AS1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Female	IV	+2.541	<.001	11	view →
COAD	All	II,III,IV	+1.005	<.001	10	view →
BLCA	Male	All	+3.071	<.001	8	view →
LUSC	Male	II,III,IV	+2.385	<.001	8	view →
THCA	All	All	+0.325	<.001	7	view →
LUAD	All	All	+0.211	<.001	5	view →
BRCA	Female	II,III,IV	+0.233	.017	4	view →
KIRC	Male	All	+0.207	<.001	3	view →
PAAD	All	All	+2.604	.003	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 9 strongest of 9 lineages.

IGFL2-AS1–HNSC

Open the HNSC breakdown →